The octapeptide hormone angiotensin II is one of the most studied peptides with the aim of designing and synthesizing non-peptide mimetics for oral administration. To achieve this, cyclizations at different positions within the peptide molecule has been a useful strategy to define the active conformation. These studies on angiotensin II led to the discovery of Sarmesin, a type II angiotensin II antagonist, and the breakthrough non-peptide mimetic Losartan, the first in a series of sartans marketed as a new generation of anti-hypertensive drugs in the 1990s. Angiotensin II receptor blockers (ARBS) and angiotensin I converting enzyme inhibitors (ACEI) were recently reported to protect hypertensive patients infected with SARS-CoV-2. The renin–angiotensin system (RAS) inhibitors reduce excess angiotensin II and increase antagonist heptapeptides alamandine and aspamandine which counterbalance angiotensin II and maintain homeostasis and vasodilation.
【저자키워드】 SARS-CoV-2, RAS, COVID 19, sartans, Angiotensin II, cyclic peptides, sarmesin, mimetics, transdermal delivery, 【초록키워드】 peptide, receptor, inhibitor, homeostasis, ACEi, administration, enzyme, blocker, PROTECT, reported, maintain, to define, reduce, anti-hypertensive drug, hypertensive patient, infected with SARS-CoV-2, 【제목키워드】 ARB, COVID-19 therapy, angiotensin, blocker, cyclic,